Type(s) of hormonal therapy-Anti-androgens-Abiraterone plus prednisone Posts on Medivizor
Navigation Menu

Type(s) of hormonal therapy-Anti-androgens-Abiraterone plus prednisone Posts on Medivizor

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Nov 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved...

Read More

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

Posted by on Jul 19, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...

Read More

Can prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?

Can prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?

Posted by on Sep 29, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the use of dexamethasone, instead of prednisone, used with abiraterone acetate (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC). This study found that prednisone to dexamethasone switch can benefit some patients with mCRPC. Some background Androgen deprivation therapy...

Read More

Can a switch between steroid drugs reduce progression during secondary hormone therapy?

Can a switch between steroid drugs reduce progression during secondary hormone therapy?

Posted by on Jun 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether switching steroid drugs during secondary hormone therapy with abiraterone (Zytiga) improves treatment response in progressing, advanced prostate cancer. Researchers concluded that a steroid switch can be effective in delaying disease progression in some men. Some background Abiraterone is a secondary...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor